Dr. Lee Cranmer, MD, PhD

Dr. Cranmer practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Cranmer's NPI, 1861465759, was assigned on February 10, 2006. Dr. Cranmer holds Washington license MD60579616.

Dr. Cranmer's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Cranmer's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Cranmer to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cranmer practices. Vendor and product names are available with a free account.

Medical oncology is Dr. Cranmer's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Cranmer is licensed in Washington.

CMS data shows 458 Medicare services from Dr. Cranmer across 5 procedure codes in 2024, for 141 Medicare patients. Medicare paid $31,208 for them. Every service was in an office.

CMS counts 141 Medicare patients who saw Dr. Cranmer in 2024. The largest group is 65 to 74, with 67 patients. 66% of them have high blood pressure, and 63% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.38, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cranmer's median patient age at 65, with 50% women.

In 2024, Dr. Cranmer wrote 99 Medicare Part D claims for 36 patients. 68% of them were for generic drugs. CMS names the drug for 29 of them, across 2 drugs with 11 or more claims each, at $11,571 in total drug cost. In 2023, CMS named 21 claims across 1 drug.

Dr. Cranmer accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cranmer as offering telehealth.

Dmand AI links 76 papers to Dr. Cranmer, published from 2010 to 2025. 2017 was the busiest year, with 8. The most frequent topics are Sarcoma, Melanoma and Antineoplastic Combined Chemotherapy Protocols. Dr. Cranmer has published most often in JAMA Oncol. Dr. Cranmer's most frequent co-authors are Elizabeth Trice Loggers, MD, PhD, Kristen Nooshin Ganjoo, MD and Edward Y. Kim, MD.

Dmand AI links Dr. Cranmer to 10 clinical trials, 4 of them phase 1/2 studies. 2 are still active or recruiting. Conditions studied include Sarcoma, Neoplasms, Connective and Soft Tissue and Dermatofibrosarcoma. University of Washington sponsors the most, 2. Open Payments lists research payments to Dr. Cranmer that name 1 trial.

CMS Open Payments shows 82 general payments to Dr. Cranmer from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 71% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $17,195. It also lists 4 research payments totaling $25,802 from 2016 to 2019, naming 1 clinical trial.